Triple-negative breast cancer (TNBC) remains the most challenging breast cancer subtype
to treat. To date, therapies directed to specific molecular targets have rarely achieved …

Breast cancer (BC) is a common cancer all over the world that affects women. BC is one of
the leading causes of cancer mortality in women, which today has decreased with the …

Human epidermal growth factor receptor 2 (HER2) protein overexpression and/or HER2
gene amplification is found in about 20% of invasive breast cancers. It is a sole predictive …

Background In metastatic breast cancer, hormone and/or human epidermal growth factor
receptor 2 (HER2)–targeted therapy decision-making is still largely based on tissue …

Purpose To provide recommendations on the appropriate use of breast tumor biomarker
assay results to guide decisions on systemic therapy for metastatic breast cancer. Methods A …

Abstract Oestrogen receptor (ER)-positive—or luminal—tumours represent around two-
thirds of all breast cancers. Luminal breast cancer is a highly heterogeneous disease …

Purpose Decisions about treatment for women with metastatic breast cancer are usually
based on the estrogen (ER), progesterone (PgR), and human epidermal growth factor …

PET imaging with 16α-18F-fluoro-17β-fluoroestradiol (18F-FES), a radiolabeled form of
estradiol, allows whole-body, noninvasive evaluation of estrogen receptor (ER). 18F-FES is …

Estrogen receptor (ESR1) drives growth in the majority of human breast cancers by binding
to regulatory elements and inducing transcription events that promote tumor growth …

Cell-free DNA (cfDNA) has the potential to inform tumor subtype classification and help
guide clinical precision oncology. Here we develop Griffin, a framework for profiling …